Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Leave a comment

Your email address will not be published. Required fields are marked *